J
Julia Hauer
Researcher at University of Düsseldorf
Publications - 55
Citations - 3364
Julia Hauer is an academic researcher from University of Düsseldorf. The author has contributed to research in topics: Medicine & Biology. The author has an hindex of 16, co-authored 32 publications receiving 2908 citations. Previous affiliations of Julia Hauer include Necker-Enfants Malades Hospital.
Papers
More filters
Journal ArticleDOI
Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1
Salima Hacein-Bey-Abina,Alexandrine Garrigue,Gary P. Wang,Jean Soulier,Annick Lim,Estelle Morillon,Emmanuelle Clappier,Laure Caccavelli,Eric Delabesse,Kheira Beldjord,Vahid Asnafi,Elizabeth Macintyre,Liliane Dal Cortivo,Isabelle Radford,Nicole Brousse,François Sigaux,Despina Moshous,Julia Hauer,Arndt Borkhardt,Bernd H. Belohradsky,Uwe Wintergerst,Maria C. Velez,Lily E. Leiva,Ricardo U. Sorensen,NM Wulffraat,Stéphane Blanche,Frederic D. Bushman,Alain Fischer,Marina Cavazzana-Calvo +28 more
TL;DR: These findings functionally specify a genetic network that controls growth in T cell progenitors and led to sustained remission in 3 of the 4 cases of T cell leukemia, but failed in the fourth.
Journal ArticleDOI
Efficacy of Gene Therapy for X-Linked Severe Combined Immunodeficiency
Salima Hacein-Bey-Abina,Julia Hauer,Annick Lim,Capucine Picard,Gary P. Wang,Charles C. Berry,Chantal Martinache,Frédéric Rieux-Laucat,Sylvain Latour,Bernd H. Belohradsky,Lily E. Leiva,Ricardo U. Sorensen,Marianne Debré,Jean-Laurent Casanova,Stéphane Blanche,Anne Durandy,Frederic D. Bushman,Alain Fischer,Marina Cavazzana-Calvo +18 more
TL;DR: After nearly 10 years of follow-up, gene therapy was shown to have corrected the immunodeficiency associated with SCID-X1 and may be an option for patients who do not have an HLA-identical donor for hematopoietic stem-cell transplantation and for whom the risks are deemed acceptable.
Journal ArticleDOI
Childhood cancer predisposition syndromes : A concise review and recommendations by the Cancer Predisposition Working Group of the Society for Pediatric Oncology and Hematology
Tim Ripperger,Stefan S. Bielack,Arndt Borkhardt,Ines B. Brecht,Ines B. Brecht,Birgit Burkhardt,Gabriele Calaminus,Klaus-Michael Debatin,Hedwig E. Deubzer,Uta Dirksen,Cornelia Eckert,Angelika Eggert,Miriam Erlacher,Gudrun Fleischhack,Michael C. Frühwald,Astrid Gnekow,Gudrun Goehring,Norbert Graf,Helmut Hanenberg,Julia Hauer,Barbara Hero,Simone Hettmer,Katja von Hoff,Martin A. Horstmann,Juliane Hoyer,Thomas Illig,Peter Kaatsch,Roland Kappler,Kornelius Kerl,Thomas Klingebiel,Udo Kontny,Uwe Kordes,Dieter Körholz,Ewa Koscielniak,Christof M. Kramm,Michaela Kuhlen,Andreas E. Kulozik,Britta Lamottke,Ivo Leuschner,Dietmar R. Lohmann,Andrea Meinhardt,Markus Metzler,Lüder Hinrich Meyer,Olga Moser,Michaela Nathrath,Charlotte M. Niemeyer,Rainer Nustede,Kristian W. Pajtler,Kristian W. Pajtler,Claudia Paret,Mareike Rasche,Dirk Reinhardt,Olaf Rieß,Alexandra Russo,Stefan Rutkowski,Brigitte Schlegelberger,Dominik T. Schneider,Reinhard Schneppenheim,Martin Schrappe,Christopher Schroeder,Dietrich von Schweinitz,Thorsten Simon,Monika Sparber-Sauer,Claudia Spix,Martin Stanulla,Doris Steinemann,Brigitte Strahm,Petra Temming,Kathrin Thomay,André O. von Bueren,Peter Vorwerk,Olaf Witt,Marcin W. Wlodarski,Willy Wössmann,Martin Zenker,Stefanie Zimmermann,Stefan M. Pfister,Stefan M. Pfister,Christian P. Kratz +78 more
TL;DR: This review summarizes the current knowledge of cancer predisposition syndromes in pediatric oncology and provides essential information on clinical situations in which a childhood cancer genetic predisposition syndrome should be suspected.
Journal ArticleDOI
A self-inactivating lentiviral vector for SCID-X1 gene therapy that does not activate LMO2 expression in human T cells
Sheng Zhou,Disha Mody,Suk See DeRavin,Julia Hauer,Taihe Lu,Zhijun Ma,Salima Hacein-Bey Abina,John T. Gray,Michael R. Greene,Marina Cavazzana-Calvo,Harry L. Malech,Brian P. Sorrentino +11 more
TL;DR: It is concluded that the CL20i4-EF1alpha-hgamma(c)OPT vector may be suitable for testing in a clinical trial based on these preclinical demonstrations of efficacy and safety.
Journal ArticleDOI
Infection Exposure Is a Causal Factor in B-cell Precursor Acute Lymphoblastic Leukemia as a Result of Pax5-Inherited Susceptibility
Alberto Martín-Lorenzo,Julia Hauer,Carolina Vicente-Dueñas,Franziska Auer,Inés González-Herrero,Idoia García-Ramírez,Sebastian Ginzel,Ralf Thiele,Stefan N. Constantinescu,Christoph Bartenhagen,Martin Dugas,Michael Gombert,Daniel Schäfer,Oscar Blanco,Andrea Mayado,Alberto Orfao,Diego Alonso-López,Javier De Las Rivas,César Cobaleda,María Begoña García-Cenador,Francisco Javier García-Criado,Isidro Sánchez-García,Arndt Borkhardt +22 more
TL;DR: It is demonstrated that delayed infection exposure is a causal factor in pB-ALL and these findings have critical implications for the understanding of the pathogenesis of leukemia and for the development of novel therapies for this disease.